

GEORGIA STATE BOARD OF OPTOMETRY
Conference Call - June 29, 2007

A conference call meeting of the Georgia State Board of Optometry was held on Friday, June 29, 2007 at 9:00 a.m. in the Professional Licensing Boards, 237 Coliseum Drive, Macon, Georgia.

The following Board members were present:

Kay Royal, President
Dudley Christie
H. Kemp Jones

Patricia Donnelly
Bill Sharpton

Administrative Staff Present:

Ellen Morris, Board Secretary, Gwen Dodson, Administrative Assistant, Wylencia Monroe, Assistant Attorney General

President Royal established that a quorum was present and the meeting was called to order at 9:00 a.m.

Public Hearing: Proposed Rule 430-10-.03

Dr. Jones moved and Dr. Christie seconded the motion and the Board voted to post the Notice of Intent to Adopt and the Notice of Hearing for the proposed rule change to rule 430-10-.03 for no less than 30 days as follows:

**NOTICE OF INTENT TO ADOPT A PROPOSED
AMENDMENT TO THE GEORGIA STATE BOARD OF OPTOMETRY RULES
CHAPTER 430-10; RULE 430-10-.03, APPROVED THERAPEUTIC DRUGS AND NOTICE
OF PUBLIC HEARING**

TO ALL INTERESTED PARTIES:

Notice is hereby given that pursuant to the authority set forth below, the Georgia State Board of Optometry (hereinafter "Board") proposes an amendment to the Georgia State Board of Optometry Rules, Chapter 430; Rule 430-10-.03 Approved Therapeutic Drugs (herein after "proposed rule amendment").

This notice, together with an exact copy of the proposed rule amendment and a synopsis of the proposed rule amendment, is being mailed to all persons who have requested, in writing, that they be placed on a mailing list. A copy of this notice, an exact copy of the proposed rule amendment, and a synopsis of the proposed rule amendment may be reviewed during normal business hours of 8:00 A.M. to 5:30 P.M., Monday through Friday, except official State holidays, at the Office of the Secretary of State, Professional Licensing Boards Division, 237 Coliseum Drive, Macon, Georgia 31217. Copies may also be requested by contacting the Board office at (478) 207-2440.

A public hearing will be held at 10:30 a.m. on August 8, 2007 at the Secretary of State's Professional Licensing Boards Division, 237 Coliseum Drive in Macon, Georgia 31217 to provide the public an opportunity to comment upon and provide input into the proposed rule amendment.

At the public hearing anyone may present data, make a statement, comment or offer a viewpoint or argument whether orally or in writing. Lengthy statements or statements of a considerable technical or economic nature, as well as previously recorded messages, must be submitted for official record. Oral statements should be concise and will be limited to five (5) minutes per person. Written comments are welcome. Such written comments must be legible and signed, should contain contact information from the maker (address, telephone number and/or facsimile number, etc.) and be actually received in the office prior to the close of business (5:30 P.M.) on July 31, 2007. Written comments should be addressed to Donald Munday, Acting Division Director, Secretary of State, Professional Licensing Boards Division, Georgia State Board of Optometry, 237 Coliseum Drive, Macon, Georgia 31217. Telephone (478) 207-2440 or fax (478) 207-1660.

GEORGIA STATE BOARD OF OPTOMETRY

Conference Call - June 29, 2007

The Board will consider the proposed rule amendment for adoption at a meeting scheduled to begin at 10:35 a.m. on August 8, 2007 at the Secretary of State's Professional Licensing Boards Division, 237 Coliseum Drive in Macon, Georgia 31217. According to the Department of Law, State of Georgia, the Georgia State Board of Optometry has the authority to adopt a proposed rule amendment to Rule 430-10-.03 pursuant to authority contained in O.C.G.A. §§ 43-30-1 and 43-30-5.

At its conference call meeting on June 29, 2007, the Georgia State Board of Optometry voted that the formulation and adoption of this rule does not impose excessive regulatory cost on any licensee and any cost to comply with the proposed rule cannot be reduced by a less expensive alternative that fully accomplishes the objectives of O.C.G.A. §§ 43-30-1 and 43-30-5.

Additionally, at the meeting, the Board voted that it is not legal or feasible to meet the objectives of O.C.G.A. §§ 43-30-1 and 43-30-5 to adopt or implement differing actions for businesses as listed in O.C.G.A. § 50-13-4(a)(3)(A), (B), (C) and (D). The formulation and adoption of these rules will impact every licensee in the same manner and each licensee is independently licensed, owned and operated in the field of optometry.

For further information, contact the Board office at (478) 207-2440.

This notice is given in compliance with O.C.G.A. § 50-13-4.

This _____ day of _____, 2007.

Donald Munday
Division Director
PROFESSIONAL LICENSING BOARDS DIVISION

Posted: _____

**SYNOPSIS OF PROPOSED REVISIONS TO THE GEORGIA STATE BOARD OF
OPTOMETRY RULES CHAPTER 430-10; RULE 430-10-.03, APPROVED THERAPEUTIC
DRUGS**

PURPOSE: The purpose of the proposed rule is to provide direction to Optometrists for prescribing therapeutic drugs.

MAIN FEATURE: The main feature of this rule is to provide direction to Optometrists for the use of certain drugs and to provide a list of pharmaceutical agents that can be used for treatment purposes.

**DIFFERENCES BETWEEN THE EXISTING RULE AND THE PROPOSED AMENDMENTS
TO THE GEORGIA STATE BOARD OF OPTOMETRY RULES, CHAPTER 430-10; RULE
430-10-.03, APPROVED THERAPEUTIC DRUGS**

NOTE: Underlined text is proposed to be added; lined through text is proposed to be deleted.

Rule 430-10-.03 Approved Therapeutic Drugs proposed addition as follows:

430-10-.03 Approved Therapeutic Drugs.

~~(1) The following pharmaceutical agents may be used for treatment purposes, including ocular pain, by any doctor of optometry who has been certified pursuant to O.C.G.A. § 43-30-1(2)(A) to use pharmaceutical agents for treatment purposes:~~

- ~~(a) acetaminophen;~~
- ~~(b) acyclovir;~~
- ~~(c) antazoline;~~
- ~~(d) atropine;~~
- ~~(e) apraclonidine;~~
- ~~(f) aspirin;~~
- ~~(g) azelastine;~~
- ~~(h) bacitracin—in ophthalmic compounds;~~
- ~~(i) betaxolol;~~
- ~~(j) bichloroacetic acid;~~
- ~~(k) bimatoprost;~~
- ~~(l) brinzolamide;~~
- ~~(m) brimonidine;~~
- ~~(n) caffeine;~~
- ~~(o) calcium chloride;~~
- ~~(p) carbachol;~~
- ~~(q) carboxymethylcellulose;~~
- ~~(r) carteolol;~~
- ~~(s) ciprofloxacin;~~
- ~~(t) codeine;~~
- ~~(u) cromolyn sodium;~~
- ~~(v) cyclopentolate;~~
- ~~(w) cyclosporine;~~
- ~~(x) dapiprazole;~~
- ~~(y) demecarium;~~
- ~~(z) dexamethasone;~~

GEORGIA STATE BOARD OF OPTOMETRY
Conference Call - June 29, 2007

(aa) diclofenac;
(bb) dihydrocodeine;
(cc) dipivefrin;
(dd) dorzolamide;
(ee) echothiophate;
(ff) emedastine;
(gg) epinastine;
(hh) epinephrine;
(ii) epinephryl borate;
(jj) erythromycin;
(kk) fenoprofen;
(ll) fluorometholone;
(mm) gatifloxacin;
(nn) gentamicin;
(oo) glycerin;
(pp) gramicidin;
(qq) homatropine;
(rr) hydrocodone;
(ss) hydrocortisone—in ophthalmic compounds;
(tt) hydroxyethylcellulose;
(uu) hydroxypropyl methylcellulose;
(vv) ibuprofen;
(ww) isofluorophate;
(xx) ketoprofen;
(yy) ketorolac tromethamine;
(zz) ketotifen fumarate;
(aaa) latanoprost;
(bbb) levobunolol;
(ccc) levofloxacin;
(ddd) levocabastine HCl;
(eee) lodoxamide;
(fff) loteprednol;
(ggg) medrysone;
(hhh) mefenamic acid;
(iii) methylcellulose;
(jjj) metipranolol;
(kkk) metronidazole;
(lll) mineral oil;
(mmm) moxifloxacin;
(nnn) naloxone;
(ooo) naphazoline;
(ppp) naproxen;
(qqq) naproxen sodium;
(rrr) natamycin;
(sss) nedocromil;
(ttt) neomycin;
(uuu) nepafenac;
(vvv) norfloxacin;
(www) ofloxacin;
(xxx) olopatadine;
(yyy) oxytetracycline;
(zzz) pemirolast;
(aaaa) pentazocine;

GEORGIA STATE BOARD OF OPTOMETRY
Conference Call - June 29, 2007

(bbbb) phenarimine;
(cccc) physostigmine;
(dddd) pilocarpine;
(eeee) polycarbophil;
(ffff) polysorbate 80;
(gggg) Polymyxin B;
(hhhh) polyvinyl alcohol;
(iiii) prednisolone;
(jjjj) proethylene glycol;
(kkkk) propoxyphene;
(llll) propylene glycol;
(mmmm) rimexolone;
(nnnn) scopolamine;
(oooo) sodium chloride;
(pppp) sulfacetamide sodium;
(qqqq) sulfisoxazole diolamine;
(rrrr) suprofen;
(ssss) timolol;
(tttt) tobramycin;
(uuuu) tramadol;
(vvvv) travoprost;
(wwww) trifluridine;
(xxxx) trimethoprim;
(yyyy) white petrolatum.

(1) Pharmaceutical agents which are used by a doctor of optometry for treatment purposes and administered orally may only be:

(a) Non-narcotic oral analgesics and Schedule III or Schedule IV controlled substances which are oral analgesics;

(b) Used for ocular pain; and

(c) Used for no more than 72 hours without consultation with the patient's physician; or

(d) Oral and topical antibiotics, antivirals, topical steroids, antifungals, antihistamines, or antiglaucoma agents related to the diagnosis or treatment of diseases and conditions of the eye and adnexa oculi except Schedule I or Schedule II controlled substances.

(2) Doctors of optometry using such oral and topical pharmaceutical agents shall be held to the same standard of care imposed by Code Section 51-1-27 as would be applied to a physician licensed under Chapter 34 of this title performing similar acts; provided, however, that a doctor of optometry shall not be authorized to treat systemic diseases.

(3) The following pharmaceutical agents may be used for treatment purposes, including ocular pain, by any doctor of optometry who has been certified pursuant to O.C.G.A. 43-30-1(2)(A) to use pharmaceutical agents for treatment purposes:

(a) topical and oral antibiotics;

(b) topical and oral antivirals;

(c) topical and oral antifungals;

GEORGIA STATE BOARD OF OPTOMETRY
Conference Call - June 29, 2007

(d) topical and oral antiallergy;

(e) topical and oral antiglaucoma;

(f) topical steroids;

(g) topical and oral nonsteroidal anti-inflammatory;

(h) oral non-narcotic analgesics;

(i) oral narcotic Schedule III or IV analgesics;

(2) An optometrist certified to use therapeutic agents pursuant to O.C.G.A. § 43-30-1(2)(A), shall only use those agents as authorized under O.C.G.A. § 43-30-1(2)(D)(E) and (F). A doctor of optometry shall not administer any pharmaceutical agent by injection.

(3) The therapeutic agents listed in subparagraph (1) above to be used as an oral analgesic for ocular pain may include Schedule III or Schedule IV.

Authority O.C.G.A. 43-30-1 and 43-30-5

BOARD MEETING DATES

Dr. Sharpton moved and Ms. Donnelly seconded and the board voted to change the Optometry Board Meeting date from July 25, 2007 to August 8, 2007.

ATTORNEY GENERAL'S OFFICE

Ms. Monroe requested the board consider a vote to withdraw the referral of the proposal that contained a detailed list of drug, because it appeared some of the drugs were misspelled. Dr. Jones moved and Dr. Christie seconded and the board voted to withdraw the referral.

Dr. Royal adjourned the meeting at 9:15 a.m.

Minutes recorded by: Ellen Morris, *Board Secretary*
Minutes reviewed and edited by: Sandy Bond, *Executive Director*

Kay F. Royal, *President*

Sandy Bond, *Executive Director*

These minutes were approved on August 8, 2007.